Kleanthis G. Xanthopoulos
Independent ChairmanDr. Kleanthis G. Xanthopoulos, Ph.D., is Chairman and Chief Executive Officer of Shoreline Biosciences Inc. He serves as Venture Partner at Analytics Ventures. He was Chief Executive Officer of IRRAS AB since June 2020 until July 01, 2021. Dr. Xanthopoulos serves as Executive Director at IRRAS AB and served as its President until June 2020. Dr. Xanthopoulos serves as an Independent Non-Executive Director at Connect Biopharma Holdings Limited since December 2020 and served as its Lead Independent Director since January 2022 until June 12, 2024 and serves as its Independent Chairman since June 12, 2024. He serves as Chairman of Stork Capital Life Sciences. He is a serial entrepreneur whose passion is building healthcare companies focused on innovation. Dr. Xanthopoulos served as Executive Chairman at IRRAS AB. Dr. Xanthopoulos serves as the Managing Director of Life Science Investments at Novera Optics, Inc. He served as an Acting Chief Executive Officer at IRRAS AB. He served as the Chief Executive Officer and President of Regulus Therapeutics Inc., from January 2009 to June 2015 and previously served same positions since December 2007. Dr. Xanthopoulos also served as Principal Financial & Accounting Officer of Regulus Therapeutics Inc. since June 21, 2013. Dr. Xanthopoulos served as Senior Vice President and Vice President at Ionis Pharmaceuticals, Inc. (alternate name, Isis Pharmaceuticals, Inc.). Dr. Xanthopoulos has experience in the biotechnology and pharmaceutical research industries as an executive. Dr. Xanthopoulos founded Sente, Inc. and is its Executive Chairman of the Board since April 2026 and served as its Chief Executive Officer and President. He served as the President and Chief Executive Officer at Regulus Therapeutics, LLC since joining in December 2007. Dr. Xanthopoulos joined Regulus in 2007. He served as a Managing Director at Enterprise Partners Venture Capital since June 2006. Dr. Xanthopoulos co-founded Anadys Pharmaceuticals Inc. in May 2000 and served as its President and Chief Executive Officer from 2000 to November 2006. From 1997 to 2000, Dr. Xanthopoulos served as Vice President of Genomics and Molecular Biology at Aurora Biosciences Corporation from 1997 to 2000. He participated in The National Institutes of Health Human Genome Project and served as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Dr. Xanthopoulos received the Ernst & Young Entrepreneur of the Year Award in Health Sciences in 2006 and was named Most Admired CEO by the San Diego Business Journal in 2013. He served as the Chairman of the Board at Bioniz Therapeutics, Inc. from 2015 to July 12, 2016. He served as Chairman of the Board of Bioniz, LLC since January 7, 2016. He had been Independent Director of Zosano Pharma Corporation since April 2013. He serves as an Executive Director of Regulus Therapeutics LLC. Dr. Xanthopoulos serves as a Member of the Executive Board at BIOCOM, Inc. Dr. Xanthopoulos is an experienced and visionary leader in the biotechnology and pharmaceutical research industries, with a strong foundation in both operations and corporate development. He had been a Managing General Partner at Cerus DMCC, a life sciences investment company, since August 2015 through 2000. Dr. Xanthopoulos had been the Chairman of Apricus Biosciences, Inc. since December 11, 2013 and had been its Director since November 17, 2011. He served as Director at Seelos Therapeutics, Inc. until January 24, 2019. He serves as a Director of Biocom SA, Southern California's Life Science Industry Association, Biotechnology Innovation Organization (formerly, Biotechnology Industry Organization) and Sente, Inc. He served as a Director of Regulus Therapeutics Inc. from January 2009 to June 1, 2015. He served as a Director of Anadys Pharmaceuticals Inc. from May 2000 to November 23, 2011 and Zosano, Inc. from October 31, 2013 to April 7, 2014. He served as a Director of Odyssey Thera, Inc. He served as a Director of Bioniz, LLC from 2015 to August 23, 2016. He served as an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Stockholm, Sweden from 1991 to 1995 and Postdoctoral Research Fellow at The Rockefeller University from 1987 to 1990. An Onassis Scholar, Dr. Xanthopoulos received B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece and received both his M.Sc. in Microbiology and Immunology from 1980 to 1982 and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos has over 45 peer review publications and several issued patents.
Positions
- Company NameConnect Biopharma Holdings LimitedStock CodeCNTBPositionIndependent ChairmanColleagues
- BDBarry David QuartCEO & Director
- DLDavid L. SzekeresPresident
- LPLisa PerazaSenior Vice President of Finance
- JCJeff CohnGeneral Counsel & Corporate Secretary
- STSean T. RistineVice President of Human Resources
- KJKaren J. WilsonIndependent Non-Executive Director
- JIJean I. LiuIndependent Director
- BGBrian Gordon FeaganMember of Scientific Advisory Board
